In Vitro Activity of Vinorelbine on Human Leukemia Cells

References

• Toso C, Lindley C. Vinorelbine: a novel vinca alkaloid. Clinical review. Am J Syst Pharma 1994; 52, 15: 1287–1304.
   Google Scholar
• Potier P. The synthesis of Navelbine-prototype of a new series of vinblastine derivatives. Semin Oncol 1989; (4) 16 suppl: 15-20.
   Google Scholar
• Schlaifer D, Cooper MR, Attal M, et al. Potential strate-gies for circumventing myeloperoxidase-catalyzed degradation of vinca alkaloids. Leukemia 1994; 8 (4): 668–671.
   PubMed Web of Science ®Google Scholar
• Thou XJ, Rahmani R. Preclinical and clinical pharmacol-ogy of Vinca alkaloids. Drug 1992; 44 (suppl 4): 1-16.
   Google Scholar
• Meininger V, Binet S, Chaineau E, Fellous A. In situ response to vinca alkaloids by microtubules in cultured post-implanted mouse embryos. Biol Cell 1990; 68 (1): 21–9.
   PubMed Web of Science ®Google Scholar
• Etièvant C, Kruczynski A, Pauwels O, Kiss R. The com-bination of tetrazolium derivative reduction (MTT) and digital cell image analysis to monitor in vitro the cytotoxicity of anti-neoplastic drugs. Anticancer Res 1991; 11: 305–312.
   PubMed Web of Science ®Google Scholar
• Gomi K, Ohno H, Nomura K, Okabe M, Kobayashi K, Niitani H. Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture. Jpn J Cancer Res 1992; 83: 532–539.
   PubMedGoogle Scholar
• Photiou A, Sheikh MN, Bafaloukos D, Retsas S. Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines. J Cancer Res Clinic Oncol 1992; 118: 249–254.
   PubMed Web of Science ®Google Scholar
• Binet S, Chaineau E, Fellus A, et al. Immunofluor-escence study of the action of navelbine, vincristine and vin-blastine on mitotic and axonal microtubules. Int J Cancer 1990; 46: 262–266.
   PubMed Web of Science ®Google Scholar
• Depierre A, Lemarie E, Dabouis G, Gamier G, Jacoulet P, Dalphin JC. Efficacy of Navelbine (NVB) in non-small cell lung cancer (NSCLC). Sem Oncol 1989; 16 (suppl 4): 26-29.
   Google Scholar
• Goss GD, Logan DM, Newman TE, Evans WK. Use of vinorelbine in non-small-cell lung cancer. Provincial Lung Disease Site Group. Cancer Prey Control 1997; 1 (1): 28–38.
   PubMedGoogle Scholar
• Aaspro MS. Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer. Oncology 1997; 11 (suppl 8): 46-49.
   Google Scholar
• Goss PE, Fine S, Gelmon K, et al. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer. Cancer Chem Pharm 1997; 41 (1): 53–60.
   PubMed Web of Science ®Google Scholar
• Conti F, Vici P. Vinorelbine in the treatment of breast cancer: current status and prospectives for the future. Clin Terapeut 1998; 149 (921): 61–74.
   PubMedGoogle Scholar
• Jones S, Winer E, Vogel C, et al. Randomized compar-ision of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995; 13 (10): 2567–2574.
   PubMed Web of Science ®Google Scholar
• Weber BL, Vogel C, Jones S, et al. Intravenous vinorel-bine as first-line and second-line therapy in advanced breast cancer. J Clinic Oncol 1995; 13 (11): 2722–2730.
   PubMed Web of Science ®Google Scholar
• Burger RA, Di Saia PJ, Roberts JA, et al. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol 1999; 72 (2): 148–153.
   PubMed Web of Science ®Google Scholar
• Bonfante V, Viviani S, Santoro A, et al. Isofosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Br J Hematol 1998; 103 (2): 533–535.
   PubMed Web of Science ®Google Scholar
• Devizzi L, Santoro A, Bonfante V, Viviani S, Bonadonna G. Vinorelbine: a new promising drug in Hodgkin's disease. Luek Lymphoma 1996; 22 (5-6): 409–414.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Schnell R, Diehl V, Engert A. New drugs in the treatment of Hodgkin's disease. Ann Oncol 1998; 9 (suppl 5): S103-S108.
   Google Scholar
• Gattei V, Bernabei PA, Pinto A, et al. Phorbol ester induced osteoclastic-like differentiation of a novel human cell line (FLG 29.1). J Cell Biol 1992; 116 (2): 437-447.
   Google Scholar
• Collins S, Gallo RC, Gallagher RE. Continous growth and differentiation of human myeloid leukaemic cells in sus-pension. Nature 1977; 270: 347–349.
   PubMed Web of Science ®Google Scholar
• Lozzio M, Lozzio B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975; 45: 321–334.
   PubMed Web of Science ®Google Scholar
• Foley GF, Lazarus H, Farber S, Geren Utzman B, Boone BA, McCarty RE. Continous colture of human Lymphoblasts from peripheral blood of a child whit acute leukemia. Cancer 1965; 18: 522–529.
   PubMed Web of Science ®Google Scholar
• Klein E, Klein G, Nadkarni JS, Nadkarni JJ, Wigzell H, Clifford P. Surface IgM-Kappa specificity on a Burkitt Lymphoma cell in vivo and in derived culture lines. Cancer Res 1968; 28: 1300–1310.
   PubMed Web of Science ®Google Scholar
• Lok MS, Koshiba H, Han T, Abe S, Minowada J, Sandberg AA. Establishment and characterization of human B-lymphocytic lymphoma cell lines (BALM-3, -4 and -5): Intraclonal variation in tha B-cell differentiation stage. Int J Cancer 1979; 24: 572–578.
   PubMed Web of Science ®Google Scholar
• Castoldi GL, Cuneo A, Lanza F, Tomasi P. Diagnosis of leukemia: morphology. Leukemia 1992; 6: 6–9.
   PubMed Web of Science ®Google Scholar
• The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Confirmation and improvement of Sokal's prognostic classification of Ph+ chronic myeloid leukemia: the value of early evaluation of the course of the disease. Ann Haematol 1991; 63: 307–311.
   Google Scholar
• Cheson BD, Bennet JM, Rai KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia (CLL). Recommendation of the NCI-Sponsored Working Group. Am J Hematol 1988;. 29: 152–163.
   Google Scholar
• Bernabei PA, Santini V, Silvestro L, et al. In vitro chemosensivity testing of leukemic cells. Development of a semiautomated colorimetric assay. Hemat Oncol 1989; 7: 243–253.
   Google Scholar
• Salmon SE. Application of the human tumour stem cell assay to new drug evaluation and screening. In Salmon SE (ed), Cloning of human stem cell. New York: Alan R. Liss Inc. 1980: 223.
   Google Scholar
• Santini V, Bernabei PA, Silvestri L, et al. In vitro chemosensivity testing of leukemic cells: prediction of response to chemoterapy in patients whit acute non-lym-phoblastic leukemia. Hemat Oncol 1989; 7: 287–293.
   PubMed Web of Science ®Google Scholar
• Preisler HD, Razza A, Gopal V. Predictive assays in acute leukemia. In: Drug resistance in leukemia and lymphoma ed. by GJL Kasper, R Pieters, PR Twentyman, LM Weisenthal and ADP Veerman. Chur: Harwood academic publisher: 17.
   Google Scholar
• Kaspers GJL, Veerman APJ, Van Zantwijk CH, et al. In vitro cellular drug resistance and prognosis in newly diag-nosed childood acute lymphoblastic leukemia. Blood 1997; 90 (7): 2723–2729.
   PubMed Web of Science ®Google Scholar
• Jehl F, Debs J, Herlin C, Quoix E, Gallion C, Monteil H. Determination of Novelbine and desacetylnovelbine in bio-logical fluids by high-performance liquid chromatography. J Cromatogr 1990; 26; 525 (1): 225-233.
   Google Scholar
• Dancey J, Steward WP. The role of vindesine in oncol-ogy—recommendations after 10 years' experience. Anticancer Drugs 1995; 6 (5): 625–636.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Ludwig WD, Thiel E, et al. Improved out-come in adult B-cell acute lymphoblastic leukemia. Blood 1996; 87 (2): 495–508.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Hoelzer D. Vindesine in the treatment of leukemia. Leuk Lymphoma 1997; 26 (5-6): 497–506.
   PubMed Web of Science ®Google Scholar
• Jaksic B, Brugiatelli M, Krc I, et al. High dose chloram-bucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna. Cancer 1997; 79 (11): 2107–2114.
   Google Scholar
• Friedenberg WR, Salzman SA, Phan SM, Burmester JK. Transforming growth factor-beta and multidrug resistance in chronic lymphocytic leukemia. Med Oncol 1999; 16 (2): 110–118.
   PubMed Web of Science ®Google Scholar
• Binet S, Chaineau E, Fellous A, et al. Immunofluorescence study of the action of navelbine, vin-cristine and vinblastine on mitotic and axonal microtubules. Int J Cancer 1990; 46 (2): 262–266.
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46 (2): 219–234.
   PubMed Web of Science ®Google Scholar